Health Canada Approves DMF Medical's memsorb CO2 Membrane Filtration Device for Sale in Canada
Wednesday, September 16, 2020
DMF Medical Incorporated, a privately held medical device company focused on making anesthesia safer, is pleased to announce it has received a Class II medical device license from Health Canada to sell its memsorb‚Ñ¢ carbon dioxide (CO2) filtration device in the Canadian market.
This milestone follows on the heels of successful ISO 13485:2016 and MDSAP certifications earlier this year. This approval is the culmination of years of research, development, and clinical validation of this next-generation solution for general anesthesia.
Dr. Michael Schmidt, founder and chief medical officer (CMO), expressed his thoughts regarding this revolutionary technology by saying, "My goal has always been to make anesthesia safer by bringing technologies like memsorb‚Ñ¢ from the bench to the bedside. The approval of memsorb‚Ñ¢ in Canada is a meaningful and crucial next step in addressing the ongoing challenges we face in anesthesia, such as our aging patient population, ongoing economic pressures, and our environmental footprint. We are thrilled to have been able to develop this first-of-its-kind technology in Nova Scotia, and are eager to share it with our colleagues across Canada and around the world."
Dr. David Roach, president, would like to thank the numerous funding partners who have supported the company through the many stages of the commercialization of memsorb‚Ñ¢. These include the Atlantic Canada Opportunities Agency (ACOA), the National Research Council of Canada — Industrial Research Assistance Program (NRC-IRAP), Sustainable Development Technologies Canada (SDTC), Next Generation Manufacturing Canada (NGen), the Dalhousie Department of Anesthesia, Pain Management and Perioperative Medicine, BioNova, and the Province of Nova Scotia, without whom this made-in-Canada solution would not have been possible.
About memsorb‚Ñ¢
memsorb‚Ñ¢ is a next-generation CO2 removal system for general anesthesia. It uses patented medical membrane technology rather than a chemical reaction to remove CO2 from the breathing circuit of anesthesia machines. memsorb‚Ñ¢ provides numerous advantages over current technologies, including longer life, elimination of waste, reduced greenhouse gas emissions, elimination of chemical byproducts, and increased machine reliability.
For more information, please contact:
Wendy Vrooman
Director of Business Development
vrooman@dmfmedical.com
www.memsorb.com
DMF Medical is a resident company at The Bays at Innovacorp.
Halifax, Nova Scotia, September 16, 2020